Online inquiry

IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4553MR)

This product GTTS-WQ4553MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CXCR4 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001008540.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7852
UniProt ID P61073
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4553MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12154MR IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MORAb-004
GTTS-WQ13581MR IVTScrip™ mRNA-Anti-IL13, QAX-576(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA QAX-576
GTTS-WQ7592MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA G-CSF
GTTS-WQ3641MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY 1187982
GTTS-WQ3050MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ11428MR IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEDI-8897
GTTS-WQ223MR IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 13C5.5
GTTS-WQ5215MR IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CAT-8015
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW